If you are not happy with the results below please do another search
…quantification ranges were 5–80 ppm and 5–270 ppm for R5 sandwich and R5 competitive, respectively. Residual GIPs immunogenicity was detected in soluble (R5 competitive) and insoluble (R5 sandwich) G and…
…development of IHAT is well underway and we were the first company to file a nano iron [IHAT nano-ferric (III)] for approval by the European Food Safety Authority. References: https://www.nhs.uk/medicines/ferrous-sulfate/…
…line with our commercial strategy”. Danilo Casadei-Massari, Nemysis’ Chairman and CEO, states: “This is an important step in the development of Nemysis, taking us from a pre-commercial, development-focused company to…
…revenues from IHAT confirming our evolution from an R&D-focused company to a commercial company. This partnership demonstrates great interest in the first product we have developed to market which, combined…
…revenues from IHAT confirming our evolution from an R&D-focused company to a commercial company. This partnership demonstrates great interest in the first product we have developed to market which, combined…
…award, the company has the option to partner with the EIC for €6m of equity funding (matched by additional private investments), on terms to be agreed, to accelerate the commercialization…
…of the portfolio and sales of each company. Nemysis Limited and Bruno Farmaceutici S.p.A. entered into the Agreement, under which both companies will cooperate on their strategic goals, and support…
DUBLIN, May 23, 2024 (Newswire.com) – Nemysis is pleased to announce the further strengthening of its IP portfolio in relation to its unique and innovative nanoparticulate oral iron supplement, IHAT…
Nutritional deficiency research for healthier living
Head Office
Suite 4.01 Ormond Building
31-36 Ormond Quay Upper
Arran Quay
Dublin 7
D07 F6DC
Ireland
© Nemysis Ltd 2024 | Web design by Genetic Digital Privacy Policy | Cookie Policy